Sponsor Study ID:
A Phase 3, Randomized, Double Blind, Adaptive, Placebo/Paclitaxel Controlled Study of AVB S6 500 in Combination With Paclitaxel in Patients With Platinum Resistant Recurrent Ovarian Cancer
This is a Phase 3 study of AVB-S6-500 in combination with paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer. This is a randomized, double-blind, placebo-controlled study to compare efficacy and tolerability of AVB-S6-500 in combination with Pac versus placebo plus Pac.
(MUSC NetID required for document access)
For more information about the trial above please contact the study team: